Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders (Q38095762)

28 August 2017

title

Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders (English)

1 reference

28 August 2017

1 reference

Laura C Politte

1 reference

28 August 2017

Christopher J McDougle

series ordinal

1 reference

28 August 2017

publication date

4 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

231

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

1023-1036

1 reference

Acute and long-term safety and tolerability of risperidone in children with autism

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Moderators, mediators, and other predictors of risperidone response in children with autistic disorder and irritability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Aripiprazole in autism spectrum disorders and fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Quetiapine in nine youths with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Epidemiology of Pervasive Developmental Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Improvement in behaviour and attention in an autistic patient treated with ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Open-label study of olanzapine in children with pervasive developmental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Effectiveness of clozapine for the treatment of aggression in an adolescent with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Olanzapine versus haloperidol in children with autistic disorder: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Ziprasidone in adolescents with autism: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Open-label quetiapine in the treatment of children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Open trial of risperidone in 24 young children with pervasive developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Case series: use of ziprasidone for maladaptive symptoms in youths with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

A systematic review of medical treatments for children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Risperidone versus haloperidol in children and adolescents with AD : a randomized, controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Risperidone in children with autism: randomized, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Paliperidone in an adult patient with Asperger syndrome: case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Aripiprazole for maladaptive behavior in pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Paliperidone for irritability in autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Paliperidone for irritability in adolescents and young adults with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-3068-Y

The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment.

21 January 2018

1 reference

12 December 2020

Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour

1 reference

12 December 2020

Clinical effects of clozapine on autistic disorder

1 reference

12 December 2020

Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders

1 reference

12 December 2020

Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait

1 reference

12 December 2020

A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.

1 reference

12 December 2020

Clozapine in the treatment of aggression in an adolescent with autistic disorder

1 reference

12 December 2020

10.1007/S00213-013-3068-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1009690486

0 references

1 reference